581. [Recent advances in high-risk prostate cancer surgery].
作者: G Ploussard.;P Sargos.;J-B Beauval.;M Rouprêt.;I Latorzeff.
来源: Cancer Radiother. 2021年25卷6-7期655-659页
The management of high-risk prostate cancer has greatly evolved in recent years. Advances in imaging helps to better define the actual aggressiveness of the disease, to plan the surgical procedure, and to improve the prognostic evaluation of this high-risk of recurrence disease. The information obtained by MRI and by targeted biopsies improves management before surgery. Advances in nuclear medicine and generalization of PSMA-PET scans are beginning to improve the initial stage of diagnosis, thanks to a better detection of lymph node and distant metastases. The oncological interest of these new imaging techniques, which then influence the therapeutic plan, remains to be defined. The curative impact of an extensive lymph node dissection, as currently recommended, remains to be proved, and recently published randomized trials do not provide firm conclusions. The new hormone therapies pave the way for an intensification of perioperative systemic treatment, with a significant action on the tumor tissue, but an impact on survival, which remains to be defined in the context of ongoing randomized trials.
582. [Impact of neck dissection in N2-3 oropharyngeal squamous cell carcinomas treated with definitive chemoradiotherapy: An observational real-life study].
作者: G Klausner.;I Troussier.;S Kreps.;E Fabiano.;O Laccourreye.;P Giraud.
来源: Cancer Radiother. 2021年25卷8期771-778页
The purpose of this study was to assess the efficacy in terms of neck failure of an initial neck dissection before definitive chemoradiotherapy in N2-3 oropharyngeal squamous cell carcinomas, as well as the dosimetric impact and the acute and delayed morbidity of this approach.
583. [Radiotherapy for oligometastatic non-small cell lung cancer patients].
作者: A Levy.;C Roux.;O Mercier.;J Issard.;A Botticella.;F Barlesi.;C Le Péchoux.
来源: Cancer Radiother. 2021年25卷6-7期517-522页
The oligometastatic disease concept suggests that patients with a limited number of metastases have a favorable prognosis. Radical local treatment of oligometastatic patients has then increased given developments in imaging (mainly positron emission tomography and brain magnetic resonance imaging) and access to effective and better tolerated treatments. Stereotactic radiotherapy has the advantage of being noninvasive, allowing a good rate of local control and a limited number of side effects. A better definition of oligometastatic disease, particularly for non-small cell lung cancer (NSCLC), has recently been published. For patients with NSCLC, two randomized phase II trials also suggested that the addition of a radical local treatment results in encouraging survival data, with a good safety profile. A single-arm phase II finally showed a benefit when combining a radical local treatment with an anti-PD1 immunotherapy. This review describes the definitions of oligometastatic disease, the main prospective findings including radiation therapy, and prospects for oligometastatic NSCLC patients.
584. [New European Medicines Agency approval: Tucatinib in association with trastuzumab and capecitabine for the treatment of HER2-positive metastatic breast cancer previously treated].585. [Targeting the cyclin-dependent kinases 4/6 in advanced breast cancers].
作者: Florence Coussy.;Elise Deluche.;Barbara Pistilli.;Sylvain Ladoire.;Jean-Marc Ferrero.;Paul Cottu.
来源: Bull Cancer. 2021年108卷9期843-854页
The historical median survival of advanced luminal breast cancer does not exceed four years. The deciphering of the mechanisms of resistance to hormone therapy has led to the development of inhibitors of cyclin D dependent kinases (CDK4 and 6). Three drugs, palbociclib, ribociclib and abemaciclib, very similar pharmacologically, have been evaluated in the context of pivotal, randomized phase III trials. Strikingly and regardless of the endocrine therapy backbone, and in both hormone-sensitive and hormone-resistant patients, the addition of a CDK4 / 6 inhibitor doubles progression-free survival with a hazard ratio always around 0.55. The benefit in overall survival begins to be demonstrated. This review presents all published results, as well as the main safety data.
587. [Neoadjuvant treatment for rectal cancer].
作者: Jean-Baptiste Bachet.;Stéphane Benoist.;Léo Mas.;Florence Huguet.
来源: Bull Cancer. 2021年108卷9期855-867页
The management of patients with locally advanced rectal cancer has improved significantly in the past few years with preoperative radiotherapy (RT) and total mesorectal excision. The rate of local recurrence is now around 5 % while the risk of metastatic recurrence has not been reduced which is about 30 %. The benefit of adjuvant chemotherapy remains questionable apart from patients with ypN+tumor after preoperative chemoradiotherapy (CRT) for whom FOLFOX is an option. In recent years, several therapeutic trials have evaluated the benefit of extending the time between the end of RT and surgery and/or the benefit of neoadjuvant chemotherapy, administered as induction (before RT) or in consolidation (after RT and before surgery). The first results of two positive phase 3 trials, PRODIGE 23 and RAPIDO, have been reported in 2020. The two regimens evaluated in these trials are markedly different but have shown that neoadjuvant chemotherapy significantly reduces the risk of distant metastasis. Current developments largely related to a de-escalation of therapy: organ conservation according to a "Watch and Wait" strategy or local resection of the scar, administration of neoadjuvant chemotherapy without RT. These therapeutic strategies have not yet been validated but should be in the news tomorrow. The purpose of this review is to present recent data reported in patients with locally advanced rectal cancer.
588. [Epidemiology and clinical features of patients with breast cancers hospitalized in the Department of Oncology in Fianarantsoa, Madagascar from 2011 to 2018].
作者: Mampionona Ranaivomanana.;Nomeharisoa Rodrigue Emile Hasiniatsy.;Hajanirina Rakotomahenina.;Florine Rafaramino.
来源: Pan Afr Med J. 2021年38卷264页
we conducted the first epidemiological study of patients with breast cancers living in Fianarantsoa. The purpose of this study was to describe the epidemiology and clinical features of these patients in the Department of Oncology Fianarantsoa.
589. [Chemotherapy for breast cancer during pregnancy: about a case].
作者: Henintsoa Murielle Rakotomalala.;Andriatsihoarana Voahary Nasandratriniavo Ramahandrisoa.;Malala Razakanaivo.;Ny Ony Andrianandrasana.;Florine Rafaramino.
来源: Pan Afr Med J. 2021年38卷255页
The management of breast cancer during pregnancy is a challenge for physicians due to mother´s desire to carry the pregnancy to term despite the need for chemotherapy. This study reports the case of a 37-year-old multiparous woman at 20 weeks and 4 days of amenorrhea (WA). She was hospitalized for dyspnoea (stage IV according to New York Heart Association (NYHA) classification). The patient had a syndrome of heavy left pleural effusion and bilateral mastitis. The diagnosis of metastatic breast cancer was retained based on cytological examination of pleural fluid and breast cytoponction revealing galactophoric carcinoma. The patient underwent pleural drainage with improvement of dyspnea but pleural fluid continued. After multidisciplinary consultation (MC), specific treatment of cancer was necessary. Five cycles of epirubicin- cyclophosphamide-5-FU-based chemotherapy was performed after the couple provided consent. Pleural fluid diminished significantly after the second cycle of treatment. After consultation with the obstetrician, chemotherapy was interrupted one month before the 37th week of amenorrhea. Pregnancy evolved favorable, vaginal birth was managed following rupture of membranes at term with good neonatal adaptation. After one-year follow-up, the mother was still on chemotherapy and the baby was in good health. Several parameters should be considered before the administration of antineoplastic agents, hence the role of early fetal and maternal monitoring. Multidisciplinary approach is recommended to support therapeutic decision and follow-up.
590. [Huge ovarian tumor in a perimenopausal woman: a case report].
作者: Hamza Messaoudi.;Khalid Guelzim.;Moad Belouad.;Abdelhamid Benlghazi.;Jaoud Kouach.
来源: Pan Afr Med J. 2021年38卷232页
Huge ovarian tumor is usually diagnosed at an advanced stage, in particular in developing countries. It can cause surgical complications. Anatomopathological examination is essential to establish the diagnosis. The role of tumor marker CA125 in a perimenopausal woman with pelvic mass has been widely debated.
591. [Therapeutic management and prognostic profile of a patient with maxillary sarcomatoid carcinoma (case report)].
作者: Zahra Sayad.;Bouchra Dani.;Rajaa El Azzouzi.;Hafsa Elouazzani.;Nadia Cherradi.;Salma Benazzou.;Malik Boulaadas.
来源: Pan Afr Med J. 2021年38卷212页
Sarcomatoid carcinoma is a rare, aggressive, malignant tumor with a poor prognosis and a very high frequency of recurrence. Carcinoma of the maxillary sinus is extremely rare. We report the case of a 42-year-old woman with left maxillary process. Biopsy revealed aggressive sarcomatoid carcinoma with a lymph-node metastasis. The patient underwent surgical excision, lymph-node dissection followed by radiotherapy with good outcome. The rarity of this site-specific cancer poses a problem of diagnosis and timely management which is still a controversial topic. However, wide surgical excision is the gold standard treatment. This study highlights the anatomoclinical peculiarities and, in particular, the prognostic features of this tumor.
593. [Breast cancer and pregnancy: about 15 cases collected at the maternity center Monastir, Tunisia].
作者: Ahmed Hajji.;Houda El Mhabrech.;Amira Daldoul.;Nada Toumia.;Awatef Hajjaji.;Manel Njima.;Fethi Jebali.;Raja Faleh.
来源: Pan Afr Med J. 2021年38卷180页
The purpose of this study was to describe the clinical, radiological, histological and therapeutic features of breast cancer diagnosed during pregnancy. We performed a review of all medical records of patients with breast cancer diagnosed during pregnancy in the Maternity and Neonatal Center, Monastir-Tunisia, over the period 2004-2019. We collected data on 15 cases. The average age of patients was 34 years; most pregnancy-associated breast cancers (PABCs) had been diagnosed during the postpartum period. Invasive ductal carcinoma was the major histological type (93% of cases), a rare case of secretory breast carcinoma had been observed. The main clinical stages were T2 and T4 breast cancer. Hormone receptor (HR)-negative breast cancers had been reported in 40% of cases, HER2-positive breast cancers in 26.6% of cases. Treatment included surgery, radiotherapy, chemotherapy and palliative chemotherapy. The median overall survival was 32.2 months. Pregnancy-associated breast cancer is a rare entity. Patients' prognosis is generally poor due to the young age at onset and a usually delayed diagnosis. Patients should participate in therapeutic decision making, which is difficult and multidisciplinary. Targeted therapy is the great hope for new therapies.
594. [Extramammary myofibroblastoma affecting the pelvic region: a case report].
作者: Kanta Ka.;Mamadou Lassana Foba.;Sidy Ka.;Mamadou Moustapha Dieng.;Papa Macoumba Gaye.;Ahmadou Dem.
来源: Pan Afr Med J. 2021年38卷154页
Mammary myofibroblastoma is a rare soft-tissue tumor. Extramammary myofibroblastomas are particularly rare. We here report the case of a 78-year-old man presenting with pelvic pain relieved by defecation or urination. Rectal examination showed a mass in front of the anterior rectal wall. The magnetic resonance imaging (MRI) showed a well-circumscribed and heterogeneous mass measuring 10 x 6 x 8cm located behind the bladder which was pushed forward in front of the rectosigmoid. Immunohistochemical analyses showed diffuse co-expression on CD34 cells and desmin, Rb expression on most cells, oestrogen receptor expression, intense and diffuse P16 expression and a ki67 proliferation index of 25%. The patient had no recurrence 8 months after radiotherapy followed by surgery. Breast myofibroblastoma is a rare and benign tumor. Recurrence is hardly observed after local treatment. This study highlights the supporting role of radiotherapy in the efficacy of surgery.
596. [New data on the molecular biology of soft tissue sarcoma].
Sarcoma consists in a group of rare malignant tumours of mesenchymal origin characterized by their vast clinical, pathological and biological heterogeneity. The pathological diagnosis of sarcoma relies classically of the differentiation features of tumour cells, with dozens of different tumour subtypes described in the last international classifications. Over the last decades, the advances in the development of new techniques of molecular biology have led to a major complexification of sarcoma classification, with the identification of multiple and specific molecular alterations that have led to significant changes for patients diagnostic, prognostic and therapeutic management. This review aims at giving an overview on the current knowledge of the molecular biology of soft tissue sarcoma, and emphasizes on their consequences for the daily management of patients.
597. [Is preoperative axillary radio-cytology justified after ACOSOG Z001?].
作者: Antoine Defer.;Vincent Tessier.;Juliette Haudebourg.;Magali Dejode.;Marie Gosset.;Emmanuel Barranger.;Yann Delpech.
来源: Bull Cancer. 2021年108卷6期605-613页
Invasive breast cancer without clinical adenopathy (cN0) is currently explored by the sentinel node (GS) technique, except in the case of positive preoperative radio-cytological screening, where axillary curage (CA) remains systematic from the outset. Since the publication of the ACOSOG-Z0011 trial, abstention from CA is possible in patients presenting less than three metastatic GS. As a result, the value of axillary radio-cytological screening is being questioned as it could potentially lead to axillary surgical over-treatment. The objective of this study was to study clinically N0 patients with positive axillary cytology and to compare it to a group of patients with positive GS.
598. [Pheochromocytomas and paragangliomas in pregnancy: About four cases and key messages on management].
作者: C Duquesnay.;S Espiard.;C Cardot-Bauters.;B Carnaille.;M Gonzalez.;M Jourdain.;M Richardson.;C Garabedian.
来源: Gynecol Obstet Fertil Senol. 2021年49卷12期881-888页
The diagnosis of a pheochromocytoma or paraganglioma secreting during pregnancy is a rare and serious situation, involving maternal-fetal prognosis. The purpose of this case series is to discuss the management of these patients.
599. [Squamous cell carcinoma of the gallbladder complicating a cystic dilation of the cystic duct and common bile duct: a case report].
作者: Mohamed Boudou.;Rachid Jabi.;Christine Kora.;Achraf Miry.;Imane Kamaoui.;Mohammed Bouziane.
来源: Pan Afr Med J. 2021年38卷144页
Congenital cystic disease of the biliary tree is a known risk factor for gallbladder cancer. We here report a case of squamous cell carcinoma of the bile duct (BD) complicating a cystic dilatation of the bile ducts in a 54-year-old woman hospitalized for biliary pancreatitis. Abdominal scanner showed nodular thickening of the fundus of the gallbladder and fusiform dilation of the cystic duct and the main bile duct (VBP) with lesion of the tail of the pancreas, initially suggesting mucinous cystadenoma. Extended cholecystectomy involving the gallbladder fossa with resection of the distal biliary tract, choledocoduodenal anastomosis with caudal splenopancreatectomy + drainage were performed. Histopathological examination of the gallbladder mass revealed moderately differentiated invasive squamous cell carcinoma without infiltration of the hepatic parenchyma. The patient underwent adjuvant chemotherapy. The patient did not have the common symptoms of gallbladder cancer. Then radiology was necessary to make a diagnosis. Surgery is the best therapeutic option for early-stage gallbladder cancer, but adjuvant chemo-radiation may also be useful in treating these patients. Cholecystectomy with resection of cystic dilatation of the bile duct in high-risk patients are the most effective means of prevention.
600. [Therapeutic outcomes of nasopharyngeal carcinomas: a single-center study conducted at the Fattouma Bourguiba University Hospital in Monastir, Tunisia].
作者: Amel El Korbi.;Sarra Ben Tkhayat.;Rachida Bouatay.;Mehdi Ferjaoui.;Naourez Kolsi.;Khaled Harrathi.;Jamel Koubaa.
来源: Pan Afr Med J. 2021年38卷143页
nasopharyngeal carcinomas (NPCs) are relatively common in the Mediterranean basin. Survival has been greatly improved by new radiation techniques and new molecular-targeted chemotherapy. The purpose of our study was to analyze the therapeutic outcomes and to describe the prognostic factors of NPCs.
|